The time to myeloid recovery after autologous hematopoietic stem cell transplantation (HSCT) is usually defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) of у0.5 ؋ 10 9 /l (ANC500). Universal documentation of ANC500 for 3 consecutive days, historically required to ensure robust myeloid recovery, has become difficult with a trend towards early discharge and outpatient HSCT. We studied 90 autografted patients to see how frequently ANC declined after having reached у0.5 ؋ 10 9 /l. ANC500 was documented on 2 and 3 consecutive days in 14 and 63 patients, respectively. ANC increased by a median of 213% from the 1st to the 2nd day (rise in 75 and unchanged in two), and by a median of 142% from the 2nd day to the 3rd (rise in 60, unchanged in one, and decline in two; higher than the 1st day in the latter three). The increase from the 1st to the 3rd day was 13-3433% (median, 557%). Thus, in all 63 patients, no decline below ANC500 was seen, and the first day with ANC500 was also the first of 3 consecutive days with ANC500. The remaining 13 patients had repeat counts 2-7 days after the 1st day with ANC500 documenting further increase in ANC with no evidence of failed engraftment. These data show that the first day with ANC500 is also consistently the first of 3 consecutive days with ANC500 in autografted patients. Therefore, the traditional definition of myeloid engraftment should be changed to consider the first day with ANC500 as the day of engraftment without necessarily documenting ANC500 on the subsequent 1-2 days. This simple change in definition has significant implications for how data are reported to transplant registries and how peerreview organizations such as the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) define completeness of data.
/l or more (ANC500). [1] [2] [3] [4] [5] This definition, as reported in the literature, is variable, and has varied from the first of 2 consecutive days with ANC over 0.5 ϫ 10 9 /l [6] [7] [8] [9] [10] [11] to the first of 7 consecutive days with ANC over 0.5 ϫ 10 9 /l. 12 Occasionally, the first day with ANC500 has been employed as adequate evidence of neutrophil recovery with no apparent requirement for subsequent documentation of ANC500. 13 The selection of the relatively arbitrary 3-day periodthe most commonly used definition -was presumably to ensure that the neutrophil recovery was robust and sustained. This was certainly logical when marrow was the source of stem cells, growth factors were not available, and the importance of an adequate progenitor cell dose for rapid and durable hematologic recovery was not fully appreciated. However, the need for this somewhat rigid definition has never been reassessed in the context of modern transplantation practices.
Why should the definition be reassessed? It is not always necessary to obtain blood counts on the 2nd and 3rd days after the ANC has reached 0.5 ϫ 10 9 /l. However, this has to be done because registries gathering transplant data (eg International Bone Marrow Transplant Registry, Autologous Blood and Marrow Transplant Registry) need blood counts on 3 consecutive days. Peer-review organizations such as the Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) require documentation of adequate neutrophil counts on 3 consecutive days. Obtaining counts on the 2 subsequent days often involves additional clinic visits, added hospital stay or home health nurse visits which may be otherwise unnecessary, entailing inconvenience and expenditure. Despite efforts to obtain counts after discharge, it is not always possible to do so, resulting in collection of data that are deemed incomplete.
We hypothesized, based on our clinical observations, that in the overwhelming majority of autografted patients, the ANC does not decline after having reached у0.5 ϫ 10 9 /l. Thus, the first day with an ANC of у0.5 ϫ 10 /l. Therefore, the definition of myeloid engraftment in autografted patients can safely be changed to the first day with ANC у0.5 ϫ 10 9 /l without necessarily having counts available on subsequent days.
Patients and methods
One hundred consecutive adult patients with malignant diseases autografted in the Hematopoietic Stem Cell Transplant Program of the Division of Hematology/Oncology at the Northwestern University Medical School and the Northwestern Memorial Hospital between February 1998 and March 2001 were studied. Adequate serial blood counts and verifiable data were available in 90 patients. Table 1 shows the patient characteristics. The conditioning regimens employed were standard, and included highdose melphalan (plasma cell dyscrasias), busulfan-etoposide (acute myeloid leukemia), busulfan-cyclophosphamide (lymphoma), carmustine-etoposide-cytarabine-melphalan (BEAM) (lymphoma, Hodgkin's disease), cyclophosphamide-carboplatin-etoposide with total-lymphoid irradiation (Hodgkin's disease), or cyclophosphamide-carboplatinthiotepa (breast cancer). All patients received G-CSF posttransplant at the dose of 5-10 g/kg subcutaneously daily from day +1 until the ANC exceeded 0.5 ϫ 10 9 /l on 3 consecutive days. G-CSF was usually administered in the evening. Therefore, the last dose of G-CSF was usually on the second day of ANC500.
In-and out-patient records were reviewed in all patients to obtain all blood counts, whether performed in the hospital laboratory (in-patient), the clinic laboratory (outpatient), or elsewhere (usually immediately after discharge, through home health agency services). Whenever multiple blood counts were available for the same day, the morning blood count was considered and the remaining counts were ignored. The ANC included segmented neutrophils, as well as bands. 
Results
Sixty-three of the 90 patients (70%) had blood counts available on the 2 consecutive days following the first day with ANC500 (3 consecutive days with ANC500). Fourteen of the remaining 27 patients had blood counts available on the day following the first day with ANC500 (2 consecutive days). The remaining 13 patients had no blood count available on the day after the first day with ANC у0.5 ϫ 10 9 /l, but had counts available 2-7 days later. Table 2 shows the day post transplant and the ANC in each of these three groups. In the group of 63 patients where the ANC was available on 3 consecutive days, the ANC increased in 61 of 63 patients and remained unchanged in two from day 1 to 2. From day 2 to day 3, the ANC increased in 60, declined in two and remained unchanged in one. In the three latter patients, the day 3 neutrophil counts were still higher than on day 1; ie у0.5 ϫ 10 9 /l. Amongst the 14 patients with two available consecutive counts, ANC was higher on day 2 than on day 1 in all. Figure 1 is a graphic representation of the upper and lower extremes of the ANC value ranges for the 3 days. All measured ANC values fell between the two lines illustrating that the first day with ANC500 was also the first of 2 or 3 consecutive days with ANC500.
Discussion
This study shows that myeloid reconstitution after autotransplantation is usually robust and predictable. Once patients start hematologic recovery, the increase is usually sustained. It is extremely uncommon for neutrophil counts to fall immediately after having recovered to ANC500.
The current accepted definition of myeloid engraftment after an autograft is the first of 3 consecutive days with ANC500. Our data show that in these patients, the first day with ANC500 is also the first day of 3 consecutive days with ANC500 because ANC does not fall below у0.5 ϫ 10 9 /l after having crossed that threshold. We therefore propose that in autografted patients, the first day with ANC500 should be considered as the day of myeloid engraftment whether ANC values are available for the next 2 consecutive days or not.
It is important to bear in mind that these patients received G-CSF until the ANC had been at least 0.5 ϫ 10 9 /l on 3 consecutive days. An ongoing retrospective review is addressing the issue of whether this is applicable to patients who receive no growth factors post transplant at all. However, since administration of growth factors after autotransplantation is almost universal, this is not likely to be an issue in the overwhelming majority of patients.
It is also unclear if this observation is applicable to allogeneic transplantation. Another ongoing study is addressing this issue. It is likely that this will be applicable to HLAidentical sibling allografts, especially peripheral blood stem cell allografts where myeloid recovery is prompt and robust, 14, 15 and probably unrelated donor transplants. It may not be applicable to cord blood allografts where hematologic reconstitution is often slow and fragile. Table 2 Absolute neutrophil count recovery in 90 autografted patients We also suggest that transplant registries and organizations, such as FAHCT, alter the way they require documentation of neutrophil recovery based upon these data. If the first day with ANC500 is accepted as the day of myeloid engraftment, the frequency of data submissions and reports that are considered incomplete or deficient would decrease without compromising the quality of the data collected (or indeed patient care).
The changed definition would save the unnecessary expense and inconvenience for patients in the form of blood draws, possibly extra hospital stay, outpatient clinic visits, or home care nurse visits. It is possible that our observation may also affect antibiotic use. In patients who are afebrile, it may be safe to discontinue antibiotics as soon as ANC500 is achieved rather than waiting for an additional day or two to see if the recovery is sustained.
